Covetrus Stock Forecast, Price & News

-0.23 (-1.39%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
64,643 shs
Average Volume
1.10 million shs
Market Capitalization
$2.24 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

Covetrus logo

About Covetrus

Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships and successful financial outcomes for veterinary professionals. The firm geographically operates through the segments: North America, Europe and Asia Pacific (APAC) & Emerging Markets. The company was founded by Benjamin J. Shaw in 2014 and is headquartered in Portland, ME.


Covetrus, Inc. (NASDAQ:CVET) CEO Sells $526,400.00 in Stock
December 28, 2021 |
Covetrus (NASDAQ:CVET) Hits New 52-Week Low at $16.58
January 13, 2022 |
Covetrus, Inc. (CVET): Hedge Funds Are Snapping Up
January 12, 2022 |
Form 8-K COVETRUS, INC. For: Jan 12 -
January 12, 2022 |
See More Headlines

Industry, Sector and Symbol

Drug stores & proprietary stores
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$4.34 billion
Cash Flow
$2.14 per share
Book Value
$12.05 per share


Net Income
$-19 million
Pretax Margin




Free Float
Market Cap
$2.24 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.31 out of 5 stars

Computer And Technology Sector

281st out of 888 stocks

Drug Stores & Proprietary Stores Industry

4th out of 10 stocks

Analyst Opinion: 3.3Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Covetrus (NASDAQ:CVET) Frequently Asked Questions

Is Covetrus a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Covetrus stock.
View analyst ratings for Covetrus
or view top-rated stocks.

How has Covetrus' stock been impacted by COVID-19?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVET stock has increased by 80.0% and is now trading at $16.27.
View which stocks have been most impacted by COVID-19

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Covetrus

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) announced its quarterly earnings data on Thursday, November, 4th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.17 by $0.03. The firm earned $1.16 billion during the quarter, compared to analysts' expectations of $1.16 billion. Covetrus had a positive trailing twelve-month return on equity of 0.94% and a negative net margin of 1.20%.
View Covetrus' earnings history

What price target have analysts set for CVET?

5 brokerages have issued twelve-month price targets for Covetrus' stock. Their forecasts range from $19.00 to $38.00. On average, they anticipate Covetrus' stock price to reach $28.60 in the next year. This suggests a possible upside of 75.8% from the stock's current price.
View analysts' price targets for Covetrus
or view top-rated stocks among Wall Street analysts.

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin C. Wolin, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Matthew J. Foulston, Chief Financial Officer & Executive Vice President
  • Steve Palmucci, Global Chief Information Officer
  • Georgina Wraight, President-Global Technology Solutions & EVP
  • Andrew B. Coxhead, Chief Accounting Officer, VP & Controller

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus CEO Benjamin Wolin on Benjamin Wolin has an approval rating of 89% among Covetrus' employees.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.05%) and Spire Wealth Management (0.00%). Company insiders that own Covetrus stock include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends for Covetrus

Which institutional investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Covetrus company stock in the last year include Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Herbert Virgin, Laura J Phillips, Michael Ellis, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
or view top insider-selling stocks.

Which institutional investors are buying Covetrus stock?

CVET stock was bought by a variety of institutional investors in the last quarter, including Spire Wealth Management.
View insider buying and selling activity for Covetrus
or or view top insider-buying stocks.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $16.27.

How much money does Covetrus make?

Covetrus has a market capitalization of $2.24 billion and generates $4.34 billion in revenue each year. The company earns $-19 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Covetrus have?

Covetrus employs 5,657 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is

Where are Covetrus' headquarters?

Covetrus is headquartered at 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at (888) 280-2221 or via email at [email protected].

This page was last updated on 1/17/2022 by Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.